In contrast, bispecific CAR-T cells targeting both EpCAM and ICAM - 1 showed enhanced antitumor activity, with the ability to prevent resistance and reduce relapse driven by heterogeneous or EpCAM-negative tumor subpopulations (45). Here, ICAM1 is linked to neoplasm.